KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to $370.5 million.

  • Neogenomics' Cost of Revenue rose 15.50% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.0 million, marking a year-over-year increase of 10.25%. This contributed to the annual value of $370.5 million for FY2024, which is 6.75% up from last year.
  • According to the latest figures from FY2024, Neogenomics' Cost of Revenue is $370.5 million, which was up 6.75% from $347.0 million recorded in FY2023.
  • Over the past 5 years, Neogenomics' Cost of Revenue peaked at $370.5 million during FY2024, and registered a low of $258.6 million during FY2020.
  • Its 3-year average for Cost of Revenue is $346.4 million, with a median of $347.0 million in 2023.
  • Data for Neogenomics' Cost of Revenue shows a peak YoY increased of 21.96% (in 2020) over the last 5 years.
  • Neogenomics' Cost of Revenue (Yearly) stood at $258.6 million in 2020, then increased by 14.97% to $297.3 million in 2021, then increased by 8.26% to $321.8 million in 2022, then rose by 7.83% to $347.0 million in 2023, then grew by 6.75% to $370.5 million in 2024.